loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Approved Drug Products containing 202714 listed in the FDA Orange Book. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Onyx Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ONYX PHARMS AMGEN (3)

    filter

    01 POWDER;INTRAVENOUS (3)

    filter

    01 RX (3)

    filter

    01 KYPROLIS (3)

    filter

    01 Yes (3)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      CARFILZOMIB

      PDF Supplier PDF
      URL Supplier Web Content
      POWDER; INTRAVENOU...
      10MG/VIAL
      2018-06-07
      202714
      KYPROLIS
      RX
      Yes
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content
      Contact Supplier
        Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
        Post an Enquiry Post an Enquiry
        Flag U.S.A
        Virtual Booth Virtual Booth
        Digital Content Digital Content

        CARFILZOMIB

        PDF Supplier PDF
        URL Supplier Web Content
        POWDER; INTRAVENOU...
        60MG/VIAL
        2012-07-20
        202714
        KYPROLIS
        RX
        Yes
        AP
        ASK
        US
        PHARMACOMPASS
        Upload
        your Marketing & Sales content
        Contact Supplier
          Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
          Post an Enquiry Post an Enquiry
          Flag U.S.A
          Virtual Booth Virtual Booth
          Digital Content Digital Content

          CARFILZOMIB

          PDF Supplier PDF
          URL Supplier Web Content
          POWDER; INTRAVENOU...
          30MG/VIAL
          2016-06-03
          202714
          KYPROLIS
          RX
          Yes
          ASK
          US
          PHARMACOMPASS
          Upload
          your Marketing & Sales content

          Looking for FDA Orange Book APPLICATION 202714

          Looking for FDA Orange Book APPLICATION 202714 3

          19

          Onyx Pharmaceuticals, based in U.S.A, is a pharmaceutical company.

          One of their notable products is CARFILZOMIB, with a corresponding application number 202714.

          Regulatory Information RX

          With a dosage strength 10MG/VIAL

          Dosage Form Route POWDER; INTRAVENOUS

          Reference Listed Drug Yes

          Approved since 2018-06-07

          18

          Onyx Pharmaceuticals, based in U.S.A, is a pharmaceutical company.

          One of their notable products is CARFILZOMIB, with a corresponding application number 202714.

          Regulatory Information RX

          With a dosage strength 60MG/VIAL

          Dosage Form Route POWDER; INTRAVENOUS

          Reference Listed Drug Yes

          Approved since 2012-07-20

          Therapeutic Equivalence (TE) Code AP

          17

          Onyx Pharmaceuticals, based in U.S.A, is a pharmaceutical company.

          One of their notable products is CARFILZOMIB, with a corresponding application number 202714.

          Regulatory Information RX

          With a dosage strength 30MG/VIAL

          Dosage Form Route POWDER; INTRAVENOUS

          Reference Listed Drug Yes

          Approved since 2016-06-03

          Post Enquiry
          POST ENQUIRY